ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1062

Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Abstract Number: 2558

Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Abstract Number: 1645

Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort
Abstract Number: 0706

Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Abstract Number: 1235

Apparent Diffusion Coefficient (ADC) from Diffusion Weighted Imaging (DWI) as an Objective Tool to Differentiate Normal Maturational Subchondral Signal from Inflammation at the Sacroiliac Joint in Youth
Abstract Number: 2400

Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept
Abstract Number: 1576

Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria
Abstract Number: 0638

Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Abstract Number: 0463

Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Abstract Number: 1690

Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
Abstract Number: 1112

AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Abstract Number: L15

AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Abstract Number: 2303

Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Abstract Number: 2574

Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract
Abstract Number: 1844

Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].